Delivery Order SPE2DB24D2106-SPE2DB26FATWB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,733.94 to DMS Pharmaceutical Group Inc. for the supply of Lidocaine 5% Patch 30s, with an ultimate completion date of September 25, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract type with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $5,481 to DMS Pharmaceutical Group Inc. for 30 units of Lidocaine 5% Patch on August 21, 2025, with an ultimate completion date of August 22, 2025. This firm fixed-price delivery order was issued without a set-aside designation and will be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, serves as the prime contractor on this order. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,164.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lidocaine 5% Patch 30s. The award, made on August 21, 2025, with an ultimate completion date of August 22, 2025, was issued under a firm fixed-price contract type with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,673.22 by the Defense Logistics Agency (DLA) on September 17, 2025. The delivery order, which carries a contract number 4569492043, calls for the supply of Lidocaine 5% Patch in quantities of 30 units, with an ultimate completion date of September 18, 2025. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on August 21, 2025, for the supply of Lidocaine 5% Patch in quantities of 30 units. This firm fixed-price delivery order, valued at $1,518.72, represents a continuation of pharmaceutical supply services under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The contract will be fulfilled at the awardee's location in Park Ridge, Illinois, with an ultimate completion date of August...
- The Defense Logistics Agency awarded a $2,183.16 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Lidocaine 5% Patch 30s. This delivery order, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, carries no set-aside designation and represents a standard procurement vehicle under DLA's pharmaceutical supply operations. The award leverages DMS...
- This is a $7,593.60 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of 4,563,767,512 units of Lidocaine 5% Patch 30s, with a completion date of February 27, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,929.24 firm fixed-price contract is for the delivery of 4564443626 - Lidocaine 5% Patch 30s, with a performance period through May 28, 2024. The contract is not set-aside. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that runs...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,796.80 contract is for the supply of 4562162772 - Lidocaine 5% Patch 30s, with a completion date of Sep 14, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The $1,518.72 firm fixed-price order is for the delivery of 4564557509 - Lidocaine 5% Patch 30s. There was no set-aside designation used for this contract. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FATWBDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,932.89 to DMS Pharmaceutical Group Inc. for Lidocaine 5% Patch 30s, with an ultimate completion date of October 20, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order will be performed in Conshohocken, Pennsylvania, and represents a routine pharmaceutical supply acquisition issued under the company's broader Indefinite Delivery Contract with DLA. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying contract, designated SPE2DR and valued at $499.99 billion, was awarded on November 13, 2025, with a completion date of December 31, 2036, and includes a 30-month base period with three 30-month option periods. Through this vehicle, DMS Pharmaceutical Group supplies a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 10/17/25 |